China Resources Pharmaceutical Group Statistics
Total Valuation
China Resources Pharmaceutical Group has a market cap or net worth of HKD 34.11 billion. The enterprise value is 132.80 billion.
Market Cap | 34.11B |
Enterprise Value | 132.80B |
Important Dates
The last earnings date was Friday, November 29, 2024.
Earnings Date | Nov 29, 2024 |
Ex-Dividend Date | Sep 10, 2024 |
Share Statistics
China Resources Pharmaceutical Group has 6.28 billion shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 6.28B |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.01% |
Owned by Institutions (%) | 7.97% |
Float | 1.82B |
Valuation Ratios
The trailing PE ratio is 8.51 and the forward PE ratio is 6.94. China Resources Pharmaceutical Group's PEG ratio is 0.94.
PE Ratio | 8.51 |
Forward PE | 6.94 |
PS Ratio | 0.13 |
PB Ratio | 0.66 |
P/TBV Ratio | 1.67 |
P/FCF Ratio | 2.00 |
P/OCF Ratio | n/a |
PEG Ratio | 0.94 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.12, with an EV/FCF ratio of 7.80.
EV / Earnings | 32.72 |
EV / Sales | 0.49 |
EV / EBITDA | 8.12 |
EV / EBIT | 10.33 |
EV / FCF | 7.80 |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 0.78.
Current Ratio | 1.37 |
Quick Ratio | 1.02 |
Debt / Equity | 0.78 |
Debt / EBITDA | 5.14 |
Debt / FCF | 4.80 |
Interest Coverage | 5.47 |
Financial Efficiency
Return on equity (ROE) is 8.94% and return on invested capital (ROIC) is 4.32%.
Return on Equity (ROE) | 8.94% |
Return on Assets (ROA) | 2.78% |
Return on Capital (ROIC) | 4.32% |
Revenue Per Employee | 3.70M |
Profits Per Employee | 55,780 |
Employee Count | 72,986 |
Asset Turnover | 0.97 |
Inventory Turnover | 6.09 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +15.29% in the last 52 weeks. The beta is 0.39, so China Resources Pharmaceutical Group's price volatility has been lower than the market average.
Beta (5Y) | 0.39 |
52-Week Price Change | +15.29% |
50-Day Moving Average | 5.51 |
200-Day Moving Average | 5.47 |
Relative Strength Index (RSI) | 50.82 |
Average Volume (20 Days) | 9,154,730 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, China Resources Pharmaceutical Group had revenue of HKD 269.14 billion and earned 4.06 billion in profits. Earnings per share was 0.64.
Revenue | 269.14B |
Gross Profit | 42.45B |
Operating Income | 12.42B |
Pretax Income | 11.44B |
Net Income | 4.06B |
EBITDA | 15.25B |
EBIT | 12.42B |
Earnings Per Share (EPS) | 0.64 |
Balance Sheet
The company has 35.54 billion in cash and 81.84 billion in debt, giving a net cash position of -46.30 billion or -7.37 per share.
Cash & Cash Equivalents | 35.54B |
Total Debt | 81.84B |
Net Cash | -46.30B |
Net Cash Per Share | -7.37 |
Equity (Book Value) | 104.35B |
Book Value Per Share | 8.27 |
Working Capital | 57.61B |
Cash Flow
In the last 12 months, operating cash flow was 19.66 billion and capital expenditures -2.63 billion, giving a free cash flow of 17.03 billion.
Operating Cash Flow | 19.66B |
Capital Expenditures | -2.63B |
Free Cash Flow | 17.03B |
FCF Per Share | 2.71 |
Margins
Gross margin is 15.77%, with operating and profit margins of 4.61% and 1.51%.
Gross Margin | 15.77% |
Operating Margin | 4.61% |
Pretax Margin | 4.25% |
Profit Margin | 1.51% |
EBITDA Margin | 5.67% |
EBIT Margin | 4.61% |
FCF Margin | 6.33% |
Dividends & Yields
This stock pays an annual dividend of 0.18, which amounts to a dividend yield of 3.26%.
Dividend Per Share | 0.18 |
Dividend Yield | 3.26% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 3 |
Payout Ratio | 23.30% |
Buyback Yield | n/a |
Shareholder Yield | 3.26% |
Earnings Yield | n/a |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
China Resources Pharmaceutical Group has an Altman Z-Score of 1.6. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.6 |
Piotroski F-Score | n/a |